Drugs / ODM-212
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07563738 | Mar 2026 → Sep 2029 expected | malignant pancreatic neoplasm, mesothelioma, non-small cell lung carcinoma | Orion Corporation, Orion Pharma | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06725758 | Oct 2023 → Dec 2027 expected | cancer | Orion Corporation, Orion Pharma | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ODM-212 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06725758 ↗ |